KholleKhokk

VIR - the fundamental play

看多
NASDAQ:VIR   Vir Biotechnology, Inc.
There is something that market is wrong about. The VIR and its blockbuster drug. This drug earns $1-1.5B per Q.
+ they are clinical stage company with Huuge innovative pipeline in HBV and HIV - treatments and VACCINES!

And market prices them like @#$! while they will earn around their own 1x market cap in 2022 and will sit with so much cash, that the current market cap of a company is HUGE misspricing.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。